|
gptkbp:instanceOf
|
gptkb:chemical_compound
antidepressant
|
|
gptkbp:approvedBy
|
gptkb:Australia
gptkb:New_Zealand
gptkb:United_Kingdom
1970s
|
|
gptkbp:ATCCode
|
N06AX03
|
|
gptkbp:brand
|
gptkb:Tolvon
gptkb:Norval
|
|
gptkbp:CASNumber
|
24219-97-4
|
|
gptkbp:chemicalFormula
|
C18H20N2
|
|
gptkbp:compatibleWith
|
gptkb:United_States
|
|
gptkbp:contraindication
|
gptkb:liver_disease
mania
history of agranulocytosis
|
|
gptkbp:discoveredBy
|
gptkb:Organon
|
|
gptkbp:eliminationHalfLife
|
21-61 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
VZJTYGJNQZHZMA-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
CN1CC2=CC=CC=C2C3=CC=CC=C3N=C1CN4CCCCC4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mianserin
|
|
gptkbp:IUPACName
|
(2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine
|
|
gptkbp:KEGGID
|
D08207
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
antihistamine
norepinephrine reuptake inhibitor
serotonin receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
264.37 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1426
4166
4023
DB06148
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
constipation
weight gain
drowsiness
dry mouth
agranulocytosis
|
|
gptkbp:synonym
|
gptkb:Mianserinum
gptkb:Org_GB_94
|
|
gptkbp:UNII
|
7RH2S63I3E
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
insomnia
anxiety disorders
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|